Bayesian Conditional Risk (Age-Adjusted Penetrance)

Why use it

Provides individualized risk estimates for pre-symptomatic counseling without predictive genetic testing. Allows meaningful quantification of reduced risk, which may alleviate anxiety and guide decisions about whether predictive testing is desired. Particularly powerful for counseling intervening relatives (e.g., at-risk sibling of an affected parent) and pedigrees with obligate carriers who died asymptomatic.

About

In autosomal dominant late-onset disorders, the a priori risk of inheriting the pathogenic variant (typically 50% from an affected parent) decreases progressively as the at-risk individual remains asymptomatic at ages when affected mutation carriers typically develop symptoms. This phenomenon is formalized using Bayes theorem: the prior (genetic) probability is conditioned on the observation that the patient is currently unaffected — a piece of clinical information that carries significant probabilistic weight. The result is a personalized "posterior" (a posteriori) risk that is lower than the prior, sometimes dramatically so in elderly asymptomatic individuals at risk for diseases with early or near-complete penetrance.

When to use

• Asymptomatic adult child of a parent with a confirmed late-onset autosomal dominant condition (HD, SCA, FALS, Lynch syndrome, FAP, BRCA, HNPCC, etc.)
• Calculating residual risk for an at-risk individual whose intervening relative (between proband and patient) died asymptomatic at advanced age
• Pedigree analysis where multiple unaffected relatives can cumulatively lower a posterior risk across a pedigree
• Pre-counseling before offering formal predictive testing protocol

Formula

Pearls & pitfalls

• Classic application: HD (100% penetrance). An at-risk individual aged 60 with no symptoms has substantial risk reduction — penetrance by age 60 is ~60-70%, dropping posterior risk from 50% to ~22-28%.
• Penetrance curves are age- and gene-specific: use published tables for each condition (e.g., HD, BRCA1/2, FAP, Lynch).
• The model assumes 0% phenocopy rate — people without the mutation do not develop identical symptoms. For common diseases (e.g., common breast cancer, dementia), phenocopies may inflate apparent penetrance, making this model less conservative.
• Multiple asymptomatic relatives can be combined as sequential Bayesian updates (use posterior of one as prior for the next).
• A prior of 25% (e.g., grandchild of affected, parent asymptomatic and untested) is equally valid as input.
• This calculation becomes irrelevant once the patient undergoes predictive genetic testing — then genetic status is known directly.

Next steps

Use the posterior risk to guide the genetic counseling session. A significantly reduced posterior probability may reassure the patient and reduce urgency for predictive testing, though testing can still be offered if desired. Note: predictive testing protocols (e.g., for HD, FAP) involve multi-session counseling with psychological support regardless of posterior risk level.

Evidence

Fundamental application of Bayesian statistics in clinical genetics. Universally recommended by ACMG and medical genetics training programs for pedigree analysis of late-onset autosomal dominant conditions. Described in all major clinical genetics textbooks. Specific penetrance data for HD from the COHORT study (2012) and PREDICT-HD study; for BRCA1/2 from Antoniou et al. (2003), Kuchenbaecker et al. (2017).

References

1. Young ID. Introduction to Risk Calculation in Genetic Counselling. 3rd ed. Oxford University Press; 2007.
2. Langbehn DR et al. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet. 2004;65(4):267-277. — link
3. Kuchenbaecker KB et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017;317(23):2402-2416. — link